AI Chips Update - AI Blueprint Revolutionizes Financial Services With NVIDIA Technology
Dataiku has introduced a new FSI Blueprint, aimed at facilitating the deployment of agentic AI systems within the financial services sector. This blueprint, enhanced by NVIDIA's accelerated computing technologies, supports banking and insurance firms in creating and managing intelligent AI agents at scale, while adhering to industry regulations. Leveraging NVIDIA's NIM microservices, NeMo, and GPU infrastructure, the blueprint offers a secure and modular framework suitable for diverse applications such as fraud detection and risk analysis. This collaboration marks a significant step in expanding AI accessibility and productivity within highly regulated industries.
last closed at $143.96 up 0.9%.
Elsewhere in the market, was a standout up 7.8% and closing at $22.08. In the meantime, trailed, down 4.6% to close at CN¥135.50. On Tuesday, the company held a special call to discuss its major asset restructuring.
NVIDIA's Blackwell architecture is set to significantly enhance AI capabilities. Learn more about its potential impact and timing by viewing our detailed narrative.
Check out our Market Insights article, 'AI Enters the 'Show Me The Money' Phase,' highlighting AI Chips' investment potential and competitors—get in fast!
finished trading at $159.13 up 2.4%.
settled at $123.24 up 1.2%. AMD announced that Nokia will use its 5th Gen EPYC™ processors for the Nokia Cloud Platform to enhance 5G infrastructure performance on 10 June 2025, just one day ago.
ended the day at €684.50 up 0.6%.
Access the full spectrum of 53 AI Chip Stocks including BE Semiconductor Industries, Entegris and Will Semiconductor by clicking on this link.
Interested In Other Possibilities? AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Sources:
Simply Wall St
"Dataiku Unveils Enterprise-Grade Blueprint to Accelerate Agentic AI in Financial Services Built with NVIDIA" from Dataiku on GlobeNewswire (published 11 June 2025)
Companies discussed in this article include NasdaqGS:INTC NasdaqGS:QCOM NasdaqGS:AMD NasdaqGS:NVDA ENXTAM:ASML and SHSE:688041.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)
When investors think of artificial intelligence (AI), names like Nvidia (NVDA), Palantir (PLTR), and Alphabet (GOOGL) typically come to mind. But AI's impact extends well beyond the traditional tech sector. A standout example is Intuitive Surgical (ISRG), the clear global leader in robotic surgery, now making significant strides in integrating AI into healthcare. The company's latest system, the da Vinci 5, incorporates AI capabilities that could unlock a powerful new and recurring revenue stream. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Despite its leadership position, Intuitive Surgical's stock remains more than 15% below its all-time high, primarily due to competitive concerns, which may offer a compelling entry point for long-term investors. Given Intuitive Surgical's strong technological moat, I believe concerns about competition are overstated. The company's sustained innovation and market leadership position it well to remain a long-term winner. Thanks to the widespread adoption of its flagship da Vinci system, Intuitive Surgical commands an estimated 60% share of the global robotic surgery market in 2024. Once a system is installed, the company benefits from a steady stream of recurring revenue through the sale of consumables such as surgical instruments. Additionally, hospitals often choose to upgrade their systems over time to stay aligned with the latest technology, further reinforcing this revenue model. In 2024, Intuitive Surgical generated $8.4 billion in revenue, marking a 17% year-over-year increase—a testament to its ability to effectively monetize its platform. But beyond the strong financials, the company's intangible advantages significantly deepen its competitive moat. Over the past three decades, the da Vinci system has amassed an extensive base of real-world clinical data, contributing to better patient outcomes—something that is difficult, if not impossible, for competitors to replicate quickly. Moreover, Intuitive Surgical is deeply embedded in healthcare systems worldwide. Hospitals invest heavily in training surgical teams, adapting clinical protocols, and integrating the technology into their workflows. This creates substantial switching costs and a high degree of operational lock-in. Even if a competitor were to offer a lower-cost alternative, the economic and logistical barriers to switching remain a significant deterrent. Launched in early 2024, the da Vinci 5 introduces advanced AI capabilities that could further solidify Intuitive Surgical's dominance in the robotic surgery market. This latest system marks a significant shift—from basic surgical automation to intelligent surgical augmentation. According to the company, the da Vinci 5 delivers 10,000 times the computing power of previous models, enabling it to process complex data in real-time and provide intelligent, context-aware support to surgeons during procedures. This enhanced computing power allows the system to capture and analyze detailed intraoperative data, which can then be used to optimize surgical workflows, tool usage, and procedural techniques. Over time, this creates a powerful data-driven flywheel, continuously improving outcomes and efficiency in the operating room, deepening Intuitive Surgical's competitive edge. Admittedly, the competitive landscape in surgical robotics is becoming increasingly dynamic. Medtronic (MDT), a long-standing medtech leader, is preparing to launch its robotic-assisted surgery (RAS) system, Hugo, with FDA approval expected later this year. Hugo is positioned to compete in soft tissue procedures such as urology and gynecology, as well as spine surgery, and is expected to leverage AI as a key differentiator. Meanwhile, Johnson & Johnson (JNJ) is advancing its Ottava system through clinical trials, targeting procedures like gastric bypass and hiatal hernia repair, directly competing with da Vinci in the minimally invasive space. Ottava features four robotic arms integrated into a standard surgical table, a design that aims to improve workflow efficiency by reducing equipment footprint in the operating room. Additionally, Stryker's Mako system continues to gain traction in orthopedic procedures, including hip, knee, spine, and shoulder surgeries. While Intuitive Surgical remains the clear leader in robotic-assisted soft tissue surgery, these emerging systems reflect a broader push by competitors to gain ground across various surgical specialties. While Intuitive Surgical's 60% market share may face some erosion as competition intensifies, the robotic surgery market is both vast and expanding, providing ample room for multiple players to thrive. Importantly, Intuitive Surgical's first-mover advantage remains a significant asset, having established deep clinical integration and brand trust over the course of several decades. Crucially, the company is consistently profitable and continues to invest heavily in research and development, reinforcing its ability to innovate and stay ahead of emerging competitors. These factors should help Intuitive Surgical sustain its leadership position even as the market evolves. On Wall Street, ISRG earns a Strong Buy consensus rating based on 18 Buy, two Hold, and one Sell ratings in the past three months. ISRG's average price target of $596.35 implies a 14.15% upside potential over the next twelve months. Earlier this week, William Blair analyst Brandon Vazquez maintained a Buy rating on ISRG. He addressed concerns over the emergence of third-party remanufactured instruments, which could threaten the company's highly profitable and recurring instruments and accessories segment. The analyst 'believes that the limited availability of FDA-cleared remanufactured instruments and the absence of third-party verification participation will likely restrict their widespread adoption. Vazquez also notes that hospitals may be hesitant to operate outside Intuitive Surgical's ecosystem due to the high costs and risks associated with robotics programs.' The launch of the da Vinci 5 marks Intuitive Surgical's formal entry into the AI space, reinforcing its position at the forefront of the evolving robotic surgery market, even as competition intensifies. That said, several risks extend beyond the competitive landscape. Despite its recent pullback, Intuitive Surgical remains richly valued, trading at a P/E ratio of 77.2, which is well above that of its industry peers, leaving limited margin for error. The company also faces external pressures, including tariffs (estimated to impact about 1.7% of revenue) and the complexities of global expansion. Additionally, it is exposed to broader healthcare and regulatory shifts, such as the potential decline in bariatric surgery volumes resulting from the increasing use of GLP-1 medications. As AI becomes more central to its platform, data privacy concerns may also present regulatory and reputational challenges. Ultimately, Intuitive Surgical's strong market leadership and early integration of AI in a large, rapidly evolving industry give me confidence in the company's long-term potential, despite the presence of near-term risks and challenges. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
AGL Energy (ASX:AGL) investors are sitting on a loss of 20% if they invested five years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But even the best stock picker will only win with some selections. At this point some shareholders may be questioning their investment in AGL Energy Limited (ASX:AGL), since the last five years saw the share price fall 39%. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Looking back five years, both AGL Energy's share price and EPS declined; the latter at a rate of 25% per year. This fall in the EPS is worse than the 9% compound annual share price fall. So the market may previously have expected a drop, or else it expects the situation will improve. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). This free interactive report on AGL Energy's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for AGL Energy the TSR over the last 5 years was -20%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! AGL Energy shareholders gained a total return of 8.9% during the year. But that return falls short of the market. But at least that's still a gain! Over five years the TSR has been a reduction of 4% per year, over five years. It could well be that the business is stabilizing. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - AGL Energy has 4 warning signs we think you should be aware of. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Bermaz Auto Berhad Full Year 2025 Earnings: Misses Expectations
Revenue: RM2.62b (down 33% from FY 2024). Net income: RM155.9m (down 55% from FY 2024). Profit margin: 5.9% (down from 8.8% in FY 2024). The decrease in margin was driven by lower revenue. EPS: RM0.13 (down from RM0.30 in FY 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 6.4%. Earnings per share (EPS) also missed analyst estimates by 8.1%. Looking ahead, revenue is expected to decline by 3.1% p.a. on average during the next 3 years, while revenues in the Specialty Retail industry in Malaysia are expected to grow by 7.6%. Performance of the Malaysian Specialty Retail industry. The company's shares are down 15% from a week ago. You should always think about risks. Case in point, we've spotted 3 warning signs for Bermaz Auto Berhad you should be aware of, and 1 of them shouldn't be ignored. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
